Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:PHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHRPhreesia$9.21-4.1%$10.09$7.77▼$32.76$583.93M0.891.30 million shs1.14 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHRPhreesia-4.27%-3.37%+7.72%-22.03%-64.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHRPhreesia$9.21-4.1%$10.09$7.77▼$32.76$583.93M0.891.30 million shs1.14 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHRPhreesia-4.27%-3.37%+7.72%-22.03%-64.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHRPhreesia 2.58Moderate Buy$20.82126.00% UpsideCurrent Analyst Ratings BreakdownLatest PHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/13/2026PHRPhreesia KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $12.004/1/2026PHRPhreesia Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform3/31/2026PHRPhreesia StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$32.00 ➝ $20.003/31/2026PHRPhreesia BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $14.003/31/2026PHRPhreesia Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $22.003/31/2026PHRPhreesia JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$24.00 ➝ $16.003/31/2026PHRPhreesia CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $10.003/31/2026PHRPhreesia Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $11.003/31/2026PHRPhreesia Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$25.00 ➝ $10.003/31/2026PHRPhreesia Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $14.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHRPhreesia$480.59M1.16$0.72 per share12.88$5.59 per share1.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHRPhreesia$2.31M$0.03307.1317.38N/A0.48%3.23%2.11%5/27/2026 (Confirmed)Latest PHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2027PHRPhreesia$0.02N/AN/AN/A$130.08 millionN/A3/30/2026Q4 2026PHRPhreesia$0.0657$0.0210-$0.0447$0.02$126.75 million$127.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPHRPhreesiaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHRPhreesia0.411.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHRPhreesia92.10%Insider OwnershipCompanyInsider OwnershipPHRPhreesia5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHRPhreesia1,78960.76 million57.42 millionOptionablePHR HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Phreesia (PHR), AbCellera Biologics (ABCL) and PACS Group Inc (PACS)May 13 at 7:54 PM | theglobeandmail.comInvestor Notice: Robbins LLP Informs Investors of the Phreesia, Inc. Class ActionMay 13 at 7:54 PM | tmcnet.comPHR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Deadline on July 13, 2026May 13 at 7:01 PM | globenewswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Phreesia, Inc. Common Stock and Sets a Lead Plaintiff Deadline of July 13, 2026May 13 at 4:03 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHRMay 12 at 5:56 PM | globenewswire.comPhreesia Transforms Patient Check-Ins Into Clinical Trial RecruitmentMay 10, 2026 | msn.comPhreesia (PHR) Slid on Guidance CutMay 8, 2026 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHRMay 7, 2026 | prnewswire.comPhreesia, Inc. (NYSE:PHR) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 6, 2026 | marketbeat.comHead-To-Head Comparison: Valion Bio, Inc. Common Stock (NASDAQ:VBIO) versus Phreesia (NYSE:PHR)May 4, 2026 | americanbankingnews.comPhreesia Sets Release Date for Fiscal First Quarter 2027 ResultsMay 1, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHRApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHRApril 28, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, ...April 22, 2026 | bakersfield.comBPhreesia (NYSE:PHR) Insider Sells $12,314.56 in StockApril 22, 2026 | insidertrades.comYvonne Hui Sells 1,327 Shares of Phreesia (NYSE:PHR) StockApril 21, 2026 | marketbeat.comPhreesia (NYSE:PHR) General Counsel Sells $55,954.56 in StockApril 21, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phreesia, Inc. - PHRApril 21, 2026 | globenewswire.comRosen Law Firm Encourages Phreesia, Inc. Investors to Inquire About Securities Class Action Investigation – PHRApril 17, 2026 | businesswire.comYvonne Hui Sells 10,063 Shares of Phreesia (NYSE:PHR) StockApril 17, 2026 | marketbeat.comDo options traders know something about Phreesia stock we don't?April 17, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHR Company DescriptionsPhreesia NYSE:PHR$9.21 -0.40 (-4.12%) Closing price 05/13/2026 03:59 PM EasternExtended Trading$9.38 +0.16 (+1.75%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
